The Journal of Infectious Diseases
Advance Access
A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates
Oleg V. Pyankov1, Sergey A. Bodnev1, Olga G. Pyankova1,2, Vladislav V. Solodkyi1, Stepan A. Pyankov1, Yin Xiang Setoh2, Valentina A. Volchkova4, Andreas Suhrbier2,3, Viktor V. Volchkov4, Alexander A. Agafonov1 and Alexander A. Khromykh2
Author Affiliations
1State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation
2Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia
3QIMR Berghofer Medical Research Institute, Brisbane, Australia
4Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France
Abstract
The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 109 KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.